¸£Àû¼§

Photo of Henrik Green

Henrik Green

Deputy Head of Department, Professor

My research aims to better understand the mechanism of action and toxicity of new psychoactive substances, drugs of abuse and cancer chemotherapy including prediction models. I also work on how to solve murders using post-mortem metabolomics and AI.

Presentation

Genetics and Toxicology in Cancer Chemotherapy and Forensic Sciences

My research is focused on finding predictive markers and understanding how pharmaceuticals and drugs yield desired and undesired effects in humans.

Everyone is different and everyone reacts differently to drugs. Our research group studies how genetic variation affects the effect and risk of side effects in cancer treatment. We also work with new psychoactive drugs (internet drugs), their toxicology and pharmacology. Our third track is genetics in a forensic perspective.

Publications

2025

Henrik Green, Mattias Persson, Maria Wikstrom, Manuela Monti (2025) Forensic Science International, Vol. 377, Article 112657 (Article in journal)
Marie Asp, Amanda Holck, Henrik Green, Asa Westrin, Margareta Reis (2025) Nordic Journal of Psychiatry (Article in journal)
Axelle Timmerman, Donna Walther, Michael H. Baumann, Henrik Green, Eline Pottie, Christophe P. Stove (2025) Analytical Chemistry, Vol. 97, p. 17872-17881 (Article in journal)
Antheia Kissopoulou, Rada Ellegård, Eva Fernlund, Jan-Erik Karlsson, Henrik Green, Cecilia Gunnarsson (2025) Genes, Vol. 16, Article 494 (Article in journal)
Manuela Monti, Tobias Rautio, Marie H. Deventer, Markus Schlapfer, Johannes Tveit, Alex J. Krotulski, Victoria Marland, Robert Reid, Niamh Nic Daeid, Craig McKenzie, Christophe P. Stove, Henrik Green, Caitlyn Norman (2025) Archives of Toxicology, Vol. 99, p. 3641-3661 (Article in journal)

News

Henrik Green.

Nerve damage from cancer treatment can be predicted

Many women treated for breast cancer using taxanes, a type of cytostatic drug, often experience side effects in the nervous system. Researchers at LiU have developed a tool that can predict the risk level for each individual.

Three men and a woman outside Campus US.

SciLifeLab establishes a new research site at LiU

Technology, expertise, methods and initiatives can be coordinated more within and between higher education institutions. ¸£Àû¼§ is now one of four new sites in the Swedish research infrastructure SciLifeLab.

Male researcher in lab, blue background light.

SEK 13 million for research into solving murders using AI

Was it murder, poisoning or was the death maybe caused by disease? Researchers have now been granted SEK 13 million from the Swedish Research Council to develop a methodology to solve crimes using detailed analyses and artificial intelligence.

Networks and collaborations

Research videos

The hunt for the new drug - Sverige forskar

The drug trade is usually one step ahead of the legislators because each preparation must be classified as a drug separately before they are banned. But now the researchers at Linköping University can make the hunt for the drugs go much faster.

Internet drugs – occurrence, pharmacology and classification as narcotic drugs

How dangerous are internet drugs really and how do they spread in society? Henrik Gréen, professor of forensic sciences, talks about the never-ending influx of new drugs, and about how his and others‘ research makes a difference in getting drugs classed as narcotic drugs and protecting lives.

About me

CV

Currently:

  • Professor in forensic sciences at Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Faculty of Medical Sciences, Linköping University.
  • Researcher / Molecular Biologist in Engineering and Genomics. Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping.

Previously:

  • 2012 - 2020: Research strategist / Molecular Biologist in Engineering and Genomics. Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping and associated with Linköping University
  • 2011 - 2012: Post-doc at Science for Life Laboratory, Division of Gene technology, Institution for Biotechnology, KTH - Royal Institute of Technology.
  • 2007 - 2012: Assistant Professor at the Division of Drug Research, Linköping University, Linköping Sweden.

Education

  • 2000 - Master of Science in Engineering Biology. Institute of Technology, Linköping University, Linköping, Sweden.    
  • 2007 - PhD in Clinical Pharmacology. Division of Clinical Pharmacology, Department of medicine and Care, Faculty of Health Sciences, Linköping University, Linköping, Sweden. 
  • 2012 - Associate Professor in Pharmacogenetics at Linköping University.

Co-workers

Organisation